CPR strongly opposes the Eliminating Thickets to Improve Competition (ETHIC) Act. Framed as procompetition reform, it undermines constitutionally guaranteed patent rights.

CPR favors the proposal that stands for reliable IP rights by reforming the Patent Trial and Appeal Board’s widely criticized invalidation of patents previously upheld by courts and predatory infringers’ abuse of PTAB.

The proposal would improve the Patent Trial and Appeal Board’s practices for instituting inter partes review challenges. It would help restore fairness, efficiency, and predictability to patent adjudication, principles that Congress pledged in the America Invents Act.

The review of USMCA must ensure full compliance with its provisions and strengthen intellectual property protections. It should hold foreign countries to their promises and require they pay their fair share for U.S. innovation.

Rep. Thomas Massie's excellent, bipartisan Restoring America’s Leadership in Innovation Act would strengthen private property rights in one’s inventions and discoveries by broadly reversing the antipatent onslaught.

U.S. innovators that participate in the standards-development process stand to suffer irreparable harm under the UK’s proposals. Meanwhile, Chinese and other foreign firms would be incentivized to inflate the number of patents—pursuing quantity over quality of patents.

Democrats own the government shutdown, demanding that extremist, exorbitant liberal policies be included in the continuing resolution--the same clean CR they have supported many times before.

Conservatives support Pres. Trump's turning down Democrats' demand that he not allow the "temporary" Biden COVID Obamacare credits to expire. The fraud-plagued subsidies cover upper middle-class earners.

Property-rights conservatives applaud the Patent Eligibility Restoration Act and the Senate Judiciary IP Subcommittee for its hearing on this fix to patent eligibility uncertainty.

Taxpayers already benefit from federally funded research, thanks to the Bayh-Dole Act. Congress wisely rejected government revenue-sharing, as it stalls innovation, jeopardizes U.S. security and opens the door for rivals to surpass us technologically.

Nearly 40 center-right groups wrote Sec. Lutnick opposing his patent tax scheme. CPR, ATR, NTU, Unleash Prosperity and others explain it's bad tax policy at odds with the Big Beautiful Bill "counterproductive in the extreme."

A system of fines on patent owners based on the valuation of their patent portfolio would upend America's proven model while harming U.S. global competitiveness.

This bill bars pharmaceutical companies from asserting more than one patent from a defined group in a drug product in litigation. It ignores that complex products, particularly in advanced technologies, usually involve multiple distinct inventions.

Patent rights themselves don't constitute a barrier to competition in the pharma space. Rather, patents incentivize investment in innovation, whose groundbreaking products promote dynamic competition.

A coalition of conservative groups voices opposition to the MFN drug pricing model. They agree that importing foreign countries' price controls will harm patients, innovation, competitiveness and the U.S. economy.

The 340B program is supposed to help hospitals care for the indigent at low or no cost, but it's routinely used fraudulently. They get medicines at low or no cost, then distribute them to hospitals in affluent areas.

Invoking 35 U.S.C. § 202 and 28 U.S.C. § 1498 to allow generic competitors to enter the market prior to drug patent expiry is a direct attack on patent rights. HHS must reject it.

Acting Director Stewart seeks to ensure PTO's fair treatment and giving weight to “settled expectations” of inventors and patent owners. She's restoring “quiet title” through reliable, secure patent rights.

MFN would embed foreign governments' socialist price controls into American law. That will punish U.S. innovators, investors and patients. Access barriers, hundreds fewer new drugs, China Rx R&D advantaged.

CMS proposes imposing price controls on new, separately patented medicines the moment they reach the market simply because they are related to older drugs.

Thirty center-right groups voiced support for bipartisan, bicameral PREVAIL, PERA, and RESTORE Patent Rights Acts.

CPR joined more than 30 allied groups advocating for the U.S. Senate to retain health savings account provisions in the budget reconciliation bill.

Conveyed strong opposition to Congress limiting the ability of businesses to deduct state and local taxes paid -- a longstanding “ordinary and necessary expense” -- in budget reconciliation.

PREVAIL reforms the Patent Trial and Appeal Board, which has been subject to abuse by patent infringers, Big Tech, Chinese national champions, and even hedge funds.

The Patent Eligibility Restoration Act the would restore the breadth and certainty of what constitutes patent-eligible subject matter. CPR strongly supports PERA.

Congressional Review Act motion to cancel EPA's waiver from Clean Air Act, which allows California's strict emissions rules to force an electric vehicle mandate on all states.

Told Sec. Lutnick that PTO's Acting Director Coke Stewart is showing strong leadership to restore fairness, clarity, and reliability to U.S. patents and for patent owners.

Warned about four bills that threaten to undermine vital foundational principles. Exposed misconceptions about the patent system and the innovation process. Urged not to weaken the framework behind centuries of American technological progress.

The RESTORE Patent Rights Act would return access to injunctions to patent owners who've proven patent validity and infringement, as it was before the courts wrongfully denied it.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

About 200 organizations wrote Congress expressing their support for eliminating the estate tax.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

CPR tells Congress the clear message in Special 301 reports must be the United States defends its citizens' IP rights abroad.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 As Congress begins work on tax legislation, this letter points out the benefits of the 2017 corporate tax rate of 21% for American competitiveness and average Americans.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 Conservative leaders offer Trump team ways to win innovation leadership by outcompeting China, the EU and others.

Conservative leaders offer Trump team ways to win innnovation leadership by outcompeting China (the EU and others)

 We urge Congress to protect U.S. national security by shoring up the policy underpinnings that will protect our country’s innovation leadership in key technologies. 

CPR agrees with bipartisan, former top PTO officials that this must be immediately withdrawn. (If there’s room, include: Its far-reaching lengths are contrary to statute.)

H.R. 3535 adds hurdles to the U.S. International Trade Commission’s ability to keep IP-infringing products out, enabling infringers to keep supply chains in China.

The Restoring America’s Leadership in Innovation Act would strengthen private intellectual property rights. RALIA would reverse the antipatent onslaught of recent years.

The Sunset Act reins in the Administrative State's rules, regulations, and guidance. They would no longer remain in force in perpetuity.

These excerpt public comments that oppose the Biden draft guidance for Bayh-Dole march-in to forcibly relicense patents if an agency disagrees with the product price.

H.R. 6758 enables property owners to hold the federal government accountable for takings. Its more efficient, uniform process secures Fifth Amendment rights.